Regeneron DRC A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration

Administered By

Awarded By

Contributors

Start/End

  • September 23, 2019 - October 31, 2021